+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of Type II diabetes mellutis with amylin agonists

Treatment of Type II diabetes mellutis with amylin agonists

Official Gazette of the United States Patent & Trademark Office Patents 1240(1), Nov 7

Methods for treating non-insulin-taking Type II diabetes mellitus which comprise administering a therapeutically effective amount of an amylin agonist.

(PDF emailed within 1 workday: $29.90)

Accession: 035980643

Download citation: RISBibTeXText

Related references

Treatment of type II diabetes mellitus with amylin agonists. Official Gazette of the United States Patent & Trademark Office Patents 1260(2), July 9, 2002

Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53 Suppl 3: S233-S238, 2004

New treatments of diabetes: the beta-amylin agonists. Annales d'Endocrinologie 69(2): 147-150, 2008

Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus. Expert Opinion on Investigational Drugs 10(9): 1641-1652, 2002

Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group. Diabetes Care 21(6): 987-993, 1998

Cigarette Smoking, Type 2 Diabetes Mellitus, and Glucagon-like Peptide-1 Receptor Agonists as a Potential Treatment for Smokers with Diabetes: An Integrative Review. Diabetes Research and Clinical Practice 2019, 2019

The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus. Hormone and Metabolic Research 31(8): 472-475, 1999

Treatment of type 2 diabetes mellitus with GLP-1 agonists. Vnitrni Lekarstvi 57(4): 411-415, 2011

GLP-1 receptor agonists in the treatment of Type 2 diabetes. Diabetes Management 3(5): 401-413, 2013

GPR119 agonists for the treatment of type 2 diabetes. Expert Opinion on Therapeutic Patents 19(10): 1339-1359, 2010

Amylin Replacement With Pramlintide in Type 1 and Type 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin Therapy. Clinical Diabetes 20(3): 137-144, 2002

GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Hormone and Metabolic Research 36(11-12): 867-876, 2005

Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?. Diabetes Technology and Therapeutics 18(11): 671-673, 2018

Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes. British Journal of Hospital Medicine 74(4): 198-201, 2013

Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus. Current Diabetes Reports 12(5): 560-567, 2013